Champions Oncology (CSBR) has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work utilizing a variety of clinically relevant radionuclides, significantly expanding the organization’s capabilities in the development and assessment of targeted radiotherapeutics. Through this license, Champions Oncology is now uniquely positioned to integrate under one roof radionuclide-based therapeutic testing with the most clinically relevant bank of patient derived xenograft models.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSBR:
- Champions Oncology collaborates with Turbine for data platform
- Champions Oncology Reports Record Revenue and Strategic Growth
- Champions Oncology price target raised to $12 from $8 at Craig-Hallum
- Champions Oncology Achieves Record Revenue and Profit
- CSBR Earnings Report this Week: Is It a Buy, Ahead of Earnings?